Mark Rothera

Insider Reports History

Location
Cambridge, MA
Signature
Daniel Chevallard, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Mark Rothera:

Company Role Class Num Shares Value Price $ Report Date Ownership
Viracta Therapeutics, Inc. President and CEO, Director Common Stock 100,000 $49,320 $0.4932 01 Dec 2023 Direct
Viracta Therapeutics, Inc. President and CEO, Director Stock Option (Right to Buy) 475,000 12 Mar 2024 Direct

Insider Reports Filed by Mark Rothera

Symbol Company Period Transactions Value $ Form Type Role Filing Time
VIRX Viracta Therapeutics, Inc. 12 Mar 2024 1 $0 4 President and CEO, Director 13 Mar 2024, 20:36
VIRX Viracta Therapeutics, Inc. 30 Nov 2023 2 +$49,362 4 President and CEO, Director 04 Dec 2023, 16:54
VIRX Viracta Therapeutics, Inc. 16 Mar 2023 1 $0 4 President and CEO, Director 17 Mar 2023, 17:05
VIRX Viracta Therapeutics, Inc. 19 Sep 2022 1 $0 4 President and CEO, Director 19 Sep 2022, 19:04
VIRX Viracta Therapeutics, Inc. 19 Sep 2022 0 $0 3 President and CEO, Director 19 Sep 2022, 18:54